• First clinical study evaluating DAV132 in patients
• Primary endpoint met: DAV132 was safe for use in hospitalized patients with several comorbidities and concomitant medications
• DAV132 protects gut bacteria from antibiotic damage and so potentially against C. difficile infection
Paris (France), 11th of February, 2020 – Da Volterra, a clinical-stage biopharmaceutical company developing innovative products to protect the intestinal microbiota from the damaging effects of antibiotics, today announced positive top-line results from a Phase 2 clinical trial ‘SHIELD’ evaluating DAV132 in patients receiving fluoroquinolone antibiotics. DAV132, Da Volterra’s lead candidate, is a novel, first-in-class, orally administered, colon-targeted adsorbent designed to protect the intestinal microbiota of patients against antibiotic-induced disruption.
Full PR available here